Get started
Author

Renu Gupta

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
2008 · Christopher Wood, Pramod Srivastava, et al. · The Lancet · 332
Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
2008 · Alessandro Testori, Jon Richards, et al. · Journal of Clinical Oncology · 257
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
2016 · Kenneth N. Olivier, David E. Griffith, et al. · American Journal of Respiratory and Critical Care Medicine · 255
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis
2018 · Ganesh Raghu, Bernt van den Blink, et al. · JAMA · 228
PDF
Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection
2013 · J P Clancy, L Dupont, et al. · Thorax · 222
PDF
Lack of Adherence to Evidence-based Treatment Guidelines for Nontuberculous Mycobacterial Lung Disease
2014 · Jennifer Adjemian, D. Rebecca Prevots, et al. · Annals of the American Thoracic Society · 147
Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection
2014 · Sasha J. Rose, Mary E. Neville, et al. · PLoS ONE · 104
PDF
Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection
2009 · Ólanrewaju O. Okusanya, Sujata M. Bhavnani, et al. · Antimicrobial Agents and Chemotherapy · 104
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study
2019 · Ganesh Raghu, Bernt van den Blink, et al. · The Lancet Respiratory Medicine · 100
Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung
2012 · Alexander J. Chou, Renu Gupta, et al. · Pediatric Blood & Cancer · 67
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis
2019 · Diana Bilton, Tacjana Pressler, et al. · Journal of Cystic Fibrosis · 57
PDF
Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
2016 · Vladimir Malinin, Mary Neville, et al. · Antimicrobial Agents and Chemotherapy · 41
Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies
2014 · Olanrewaju O. Okusanya, Sujata M. Bhavnani, et al. · Antimicrobial Agents and Chemotherapy · 27
A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
2008 · L. Dupont, P. Minic, et al. · Journal of Cystic Fibrosis · 25
Phase 3 Efficacy and Safety Data From Randomized, Multicenter Study of Liposomal Amikacin for Inhalation (arikace) Compared With Tobi (r) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
2013 · Diana Bilton, T. Pressler, et al. · Pediatric Pulmonology · 18
Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung
2007 · A. J. Chou, M. D. Bell, et al. · Journal of Clinical Oncology · 15
Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized phase III trial in stage IV melanoma
2006 · J. Richards, A. Testori, et al. · Journal of Clinical Oncology · 15
Autologous renal cell cancer vaccines using heat shock protein-peptide complexes
2006 · Maryam Aalamian, Ephraim Fuchs, et al. · Urologic Oncology Seminars and Original Investigations · 13
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies
2019 · Robert J. Kaner, Ednan K. Bajwa, et al. · American Journal of Respiratory and Critical Care Medicine · 12
Evaluation Of Two Phase II Blinded and Placebo-Controlled Studies Of Nebulized Liposomal Amikacin (Arikace") In The Treatment Of Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
2010 · Lieven J. Dupont, John P. Clancy, et al. · 12
Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study
2014 · Dirk Wagner, Jakko van Ingen, et al. · European Respiratory Journal · 11
A multi-cycle open label study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
2010 · P. Minic, S. Fustic, et al. · Journal of Cystic Fibrosis · 8
PDF
WS7.3 Once-daily liposomal amikacin for inhalation is noninferior to twice-daily tobramycin inhalation solution in improving pulmonary function in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa
2014 · D. Bilton, T. Pressler, et al. · Journal of Cystic Fibrosis · 5
PDF
Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension of Liposomal Amikacin for Inhalation (LAI) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease (NTM-LD)
2014 · Kenneth N. Olivier, Renu Gupta, et al. · 4
217* A multi-cycle open label study of nebulized liposomal amikacin (Arikace(tm)) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
2011 · P. Minic, S. Fustik, et al. · Journal of Cystic Fibrosis · 4
PDF
Works count: 32
Citation count: 2,090
H-index: 15
I10-index: 21
Year
Topic
Type